In vivo effect of FK506 on human pancreatic islets

Camillo Ricordi, Y. Zeng, Rodolfo Alejandro, A. Tzakis, R. Venkataramanan, J. Fung, D. Bereiter, D. H. Mintz, T. E. Starzl

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the in vivo effect of FK506 on human pancreatic islets. Twenty-five nude mice were made diabetic by one intravenous injection of streptozotocin. Approximately 600 islets were administered in the renal subcapsular space 3-5 days following streptozotocin administration. One week after transplantation, the mice were divided in four groups. In group 1, the animals received 1 injection of 0.5 ml of diluent i.p. daily for one week. In groups 2, 3, and 4 the treatments were daily i.p. injection of 0.3, 1, and 3 mg/kg FK506, respectively. After treatment, the functional integrity of the transplanted human islets was tested by measuring the plasma glucose and human C-peptide response to intraperitoneal glucose injection in groups 1 and 4. IPGTT alone was assessed in groups 2 and 3. The results indicate that i.p. administration of FK506 for one week at a dose 0.3 mg/kg/day did not result in any significant alteration of glucose disappearance and C-peptide response to IPGTT. Higher doses of FK506 produced a significant delay in glucose disappearance in groups 3 and 4, and a significant inhibition of glucose-mediated C-peptide response in group 4.

Original languageEnglish
Pages (from-to)519-522
Number of pages4
JournalTransplantation
Volume52
Issue number3
StatePublished - Oct 21 1991

Fingerprint

Tacrolimus
Islets of Langerhans
C-Peptide
Glucose
Streptozocin
Injections
Intraperitoneal Injections
Nude Mice
Intravenous Injections
Transplantation
Kidney
Therapeutics

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Ricordi, C., Zeng, Y., Alejandro, R., Tzakis, A., Venkataramanan, R., Fung, J., ... Starzl, T. E. (1991). In vivo effect of FK506 on human pancreatic islets. Transplantation, 52(3), 519-522.

In vivo effect of FK506 on human pancreatic islets. / Ricordi, Camillo; Zeng, Y.; Alejandro, Rodolfo; Tzakis, A.; Venkataramanan, R.; Fung, J.; Bereiter, D.; Mintz, D. H.; Starzl, T. E.

In: Transplantation, Vol. 52, No. 3, 21.10.1991, p. 519-522.

Research output: Contribution to journalArticle

Ricordi, C, Zeng, Y, Alejandro, R, Tzakis, A, Venkataramanan, R, Fung, J, Bereiter, D, Mintz, DH & Starzl, TE 1991, 'In vivo effect of FK506 on human pancreatic islets', Transplantation, vol. 52, no. 3, pp. 519-522.
Ricordi C, Zeng Y, Alejandro R, Tzakis A, Venkataramanan R, Fung J et al. In vivo effect of FK506 on human pancreatic islets. Transplantation. 1991 Oct 21;52(3):519-522.
Ricordi, Camillo ; Zeng, Y. ; Alejandro, Rodolfo ; Tzakis, A. ; Venkataramanan, R. ; Fung, J. ; Bereiter, D. ; Mintz, D. H. ; Starzl, T. E. / In vivo effect of FK506 on human pancreatic islets. In: Transplantation. 1991 ; Vol. 52, No. 3. pp. 519-522.
@article{6441bc1bcd6e40839d878f9e647c345a,
title = "In vivo effect of FK506 on human pancreatic islets",
abstract = "The purpose of this study was to evaluate the in vivo effect of FK506 on human pancreatic islets. Twenty-five nude mice were made diabetic by one intravenous injection of streptozotocin. Approximately 600 islets were administered in the renal subcapsular space 3-5 days following streptozotocin administration. One week after transplantation, the mice were divided in four groups. In group 1, the animals received 1 injection of 0.5 ml of diluent i.p. daily for one week. In groups 2, 3, and 4 the treatments were daily i.p. injection of 0.3, 1, and 3 mg/kg FK506, respectively. After treatment, the functional integrity of the transplanted human islets was tested by measuring the plasma glucose and human C-peptide response to intraperitoneal glucose injection in groups 1 and 4. IPGTT alone was assessed in groups 2 and 3. The results indicate that i.p. administration of FK506 for one week at a dose 0.3 mg/kg/day did not result in any significant alteration of glucose disappearance and C-peptide response to IPGTT. Higher doses of FK506 produced a significant delay in glucose disappearance in groups 3 and 4, and a significant inhibition of glucose-mediated C-peptide response in group 4.",
author = "Camillo Ricordi and Y. Zeng and Rodolfo Alejandro and A. Tzakis and R. Venkataramanan and J. Fung and D. Bereiter and Mintz, {D. H.} and Starzl, {T. E.}",
year = "1991",
month = "10",
day = "21",
language = "English",
volume = "52",
pages = "519--522",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - In vivo effect of FK506 on human pancreatic islets

AU - Ricordi, Camillo

AU - Zeng, Y.

AU - Alejandro, Rodolfo

AU - Tzakis, A.

AU - Venkataramanan, R.

AU - Fung, J.

AU - Bereiter, D.

AU - Mintz, D. H.

AU - Starzl, T. E.

PY - 1991/10/21

Y1 - 1991/10/21

N2 - The purpose of this study was to evaluate the in vivo effect of FK506 on human pancreatic islets. Twenty-five nude mice were made diabetic by one intravenous injection of streptozotocin. Approximately 600 islets were administered in the renal subcapsular space 3-5 days following streptozotocin administration. One week after transplantation, the mice were divided in four groups. In group 1, the animals received 1 injection of 0.5 ml of diluent i.p. daily for one week. In groups 2, 3, and 4 the treatments were daily i.p. injection of 0.3, 1, and 3 mg/kg FK506, respectively. After treatment, the functional integrity of the transplanted human islets was tested by measuring the plasma glucose and human C-peptide response to intraperitoneal glucose injection in groups 1 and 4. IPGTT alone was assessed in groups 2 and 3. The results indicate that i.p. administration of FK506 for one week at a dose 0.3 mg/kg/day did not result in any significant alteration of glucose disappearance and C-peptide response to IPGTT. Higher doses of FK506 produced a significant delay in glucose disappearance in groups 3 and 4, and a significant inhibition of glucose-mediated C-peptide response in group 4.

AB - The purpose of this study was to evaluate the in vivo effect of FK506 on human pancreatic islets. Twenty-five nude mice were made diabetic by one intravenous injection of streptozotocin. Approximately 600 islets were administered in the renal subcapsular space 3-5 days following streptozotocin administration. One week after transplantation, the mice were divided in four groups. In group 1, the animals received 1 injection of 0.5 ml of diluent i.p. daily for one week. In groups 2, 3, and 4 the treatments were daily i.p. injection of 0.3, 1, and 3 mg/kg FK506, respectively. After treatment, the functional integrity of the transplanted human islets was tested by measuring the plasma glucose and human C-peptide response to intraperitoneal glucose injection in groups 1 and 4. IPGTT alone was assessed in groups 2 and 3. The results indicate that i.p. administration of FK506 for one week at a dose 0.3 mg/kg/day did not result in any significant alteration of glucose disappearance and C-peptide response to IPGTT. Higher doses of FK506 produced a significant delay in glucose disappearance in groups 3 and 4, and a significant inhibition of glucose-mediated C-peptide response in group 4.

UR - http://www.scopus.com/inward/record.url?scp=0025942662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025942662&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 519

EP - 522

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -